Natpara® (parathyroid hormone) for the Treatment of Hypoparathyroidism
Natpara® (parathyroid hormone), a subcutaneous injection indicated for the treatment of hypoparathyroidism, was discovered and developed by NPS Pharmaceuticals that was acquired by Shire in February 2015.
Natesto Nasal Gel for the Treatment of Men with Low Testosterone
Natesto (testosterone, formerly known as CompleoTRT) is the only FDA-approved nasal gel for treatment of adult males with conditions associated with deficiency or absence of endogenous testosterone.
Aveed (testosterone undecanoate) for the Treatment of Men with Hypogonadism
Aveed (testosterone undecanoate) is a testosterone replacement therapy indicated for the treatment of hypogonadism in adult men who are associated with a deficiency or absence of the male hormone testosterone.
Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome
Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome.
Signifor (Pasireotide) – Treatment for Cushing’s Disease
Signifor (SOM230 / Pasireotide) is a somatostatin analogue indicated for the treatment of patients with Cushing's disease for whom surgery has failed. The drug is developed and manufactured by Novartis.